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Background: While existing psychological treatments for depression are effective for many, a significant proportion
of depressed individuals do not respond to current approaches and few remain well over the long-term.
Anhedonia (a loss of interest or pleasure) is a core symptom of depression which predicts a poor prognosis but has
been neglected by existing treatments. Augmented Depression Therapy (ADepT) has been co-designed with
service users to better target anhedonia alongside other features of depression. This mixed methods pilot trial aims
to establish proof of concept for ADepT and to examine the feasibility and acceptability of a future definitive trial
evaluating the clinical and cost-effectiveness of ADepT, compared to an evidence-based mainstream therapy
(Cognitive Behavioural Therapy; CBT) in the acute treatment of depression, the prevention of subsequent depressive
relapse, and the enhancement of wellbeing.
Methods: We aim to recruit 80 depressed participants and randomise them 1:1 to receive ADepT (15 weekly acute
and 5 booster sessions in following year) or CBT (20 weekly acute sessions). Clinical and health economic assessments
will take place at intake and at 6-, 12-, and 18-month follow-up. Reductions in PHQ-9 depression severity and increases
in WEMWBS wellbeing at 6-month assessment (when acute treatment should be completed) are the co-primary
outcomes. Quantitative and qualitative process evaluation will assess mechanism of action, implementation issues, and
contextual moderating factors. To evaluate proof of concept, intake-post effect sizes and the proportion of individuals
showing reliable and clinically significant change on outcome measures in each arm at each follow-up will be
reported. To evaluate feasibility and acceptability, we will examine recruitment, retention, treatment completion, and
data completeness rates and feedback from patients and therapists about their experience of study participation and
therapy. Additionally, we will establish the cost of delivery of ADepT.
Discussion: We will proceed to definitive trial if any concerns about the safety, acceptability, feasibility, and proof of
concept of ADepT and trial procedures can be rectified, and we recruit, retain, and collect follow-up data on at least
60% of the target sample.
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Depression is a debilitating, chronically recurring, and
common condition (UK point prevalence 2.6%; estimated
lifetime risk 35%) [1–3]. It is a significant predictor of sui-
cide, working days lost, and poor physical health, account-
ing for 17% of UK disability and predicted to become the
leading worldwide contributor to disability by 2020 [4–7].
Depression is estimated to cost the UK economy £12 bil-
lion annually [8] and is not satisfactorily treated by current
psychosocial/pharmacological treatments (only 50% re-
sponse rates; amongst responders 50% relapse within 2
years) [9, 10]. It remains unclear if existing treatments lead
to markedly improved outcomes relative to placebo con-
trol conditions, except for the most severe cases [11–13].
There is a pressing need to improve treatment outcomes,
both to reduce symptom severity and the disability burden
associated with the disorder. One way to improve out-
comes is to target features of depression that have been
neglected in existing treatments but are clinically import-
ant (i.e. they predict depression prognosis and are judged
by clients as key elements to repair to lead to full
recovery).
One such feature of depression is anhedonia, defined as
a loss of interest or pleasure in normally enjoyable activ-
ities [14]. Anhedonia is one of the two cardinal symptoms
required to be diagnosed with depression. It is part of
broader disturbances in depression of the positive valence
system (PVS) [15] which regulates reward-seeking, con-
summatory behaviour and reward/habit learning in posi-
tive motivational contexts and helps shape a broader
sense of wellbeing (experiencing positive mood, having
meaning and purpose, and feeling socially connected)
[16].
Anhedonia is a prevalent feature of depression, with ap-
proximately 95% of affected individuals reporting some loss
of interest or pleasure [17] and approximately 35% showing
severe anhedonic symptoms [18]. Anhedonia symptoms
and broader wellbeing deficits predict depression onset,
treatment response, and recurrence [19–21]. Service users
report that repairing anhedonia/wellbeing is a key compo-
nent of recovery, over and above reduction in other depres-
sive symptoms [22, 23]. Despite the importance of PVS
deficits, they are not explicitly targeted by mainstream
treatments for depression [19–21]. For example, Cognitive
Behavioural Therapy (CBT) [24] targets changing negative
cognitions to reduce negative mood (i.e. the negative
valence system; NVS) [15] and pays less attention to repair-
ing anhedonia/wellbeing (i.e. the PVS). Basic science find-
ings demonstrate that the NVS and PVS are partly
dissociable [25–27]. Therefore, treatments primarily redu-
cing one will not necessarily build the other [19].
Innovative treatments need to be developed that sim-
ultaneously target reducing negativity and building posi-
tivity [19, 20, 28]. Simultaneously targeting positive andnegative valence system deficits has the potential to im-
prove acute treatment outcomes, protect individuals
from subsequent relapse, enhance recovery, and reduce
the disability burden from depression.
Augmented Depression Therapy (ADepT) has therefore
been developed to simultaneously target positive and nega-
tive valence system deficits, following guidance regarding
the development of complex interventions [29]. ADepT de-
sign was informed by (i) translating findings from basic
science research characterising PVS deficits in depres-
sion (cf., [30]) and (ii) co-designing the intervention with
service users and other stakeholders to maximise subse-
quent uptake [31–33]. The design process followed the
principles of Intervention Mapping [34]. An iterative
process of stakeholder consultation, literature review,
and analysis of the local context was conducted to de-
velop the ADepT protocol, updating a logic model of
the intervention as we went.
ADepT is a solution-focused, cognitively augmented,
behavioural activation individual therapy approach, con-
sisting of 15 acute treatment sessions and up to 5
booster sessions. Clients clarify what is important to
them in vocation, relationship, hobbies, and self-care do-
mains (their values); set behavioural goals consistent
with these values; break these goals into steps; and sys-
tematically work towards completing these steps. Clients
are encouraged to build the capability, opportunity, and
motivation to carry out each action step [35]. Therapists
support the client to understand how patterns of think-
ing and behaviour help and hinder them from fully tak-
ing opportunities to enhance positive mood (thriving)
and overcoming challenges to minimise negative mood
(being resilient)(see intervention description below for
full details; see Fig. 1 for logic model of the approach).
Given economic pressures on health care provision,
ADepT was designed to be cost neutral in comparison
to other established psychosocial treatments. If ADepT
is cost neutral and leads to superior outcomes compared
to existing treatments, then it would be the preferred
approach. Taking into account the importance clients
place on repairing anhedonia/wellbeing deficits to
enhance recovery, improvements in wellbeing and re-
duction in depression symptoms were set as co-primary
outcomes for ADepT.
We have conducted a case series evaluation of the
ADepT treatment protocol on 13 currently depressed
patients to preliminarily assess its feasibility, acceptabil-
ity, and clinical efficacy [36]. All patients completed
treatment and judged the therapy as acceptable. There
were significant improvements in levels of wellbeing and
reductions in anhedonia symptoms and depression
symptoms, each of a large effect size according to
Cohen’s rules of thumb [37]. A majority of participants
showed reliable or reliable and clinically significant
Fig. 1 Logic model of ADepT
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ation on any of the outcome measures (cf., [38]).
Follow-up assessments at 1 year indicate that these gains
in ADepT were largely preserved. We benchmarked the
case series outcomes against findings from the COBRA
trial evaluating BA and CBT in the treatment of depres-
sion [39]. ADepT and both arms of the COBRA trial
showed broadly comparable depression outcomes (all of
a large effect size). However, anhedonia outcomes were
superior for ADepT (a large effect size) compared to the
(negligible) effect sizes found in both arms of the
COBRA trial.
Next steps in evaluating ADepT protocol
The ultimate ambition is to conduct a randomised con-
trolled trial evaluating if ADepT is clinically effective
and cost effective, relative to existing treatments such as
CBT. However, uncertainties about the ADepT interven-
tion remain and refinements may need to be made be-
fore proceeding to full trial. This pre-trial work includes
further establishment of proof-of-concept, feasibility,
and acceptability; refinement of the training and supervi-
sion pathway; development of a fidelity assessment tool;
and estimation of likely cost and cost effectiveness. Un-
certainties about trial design also need to be resolved, in-
cluding the following: can participants be recruited to
time and target; are clients willing to be randomised to
CBT versus ADepT; is the measurement burden accept-
able; are allocation, blinding, and health economics pro-
cedures fit for purpose; what primary outcomemeasure(s) should be used; and what counts as mini-
mum clinically important difference on these measures
(using this information to inform sample size calculation
for a subsequent trial). The proposed pilot trial (aiming
to recruit 80 depressed participants) will address these
issues.
The following continuation criteria must have been
met to proceed to definitive trial without modification:
1. Trial and ADepT treatment participation do not
lead to serious negative consequences for
participants (unexpected, clearly trial- or treatment-
related serious adverse reaction).
2. All serious concerns about the acceptability,
feasibility, and proof of concept of the ADepT
treatment protocol and the trial design can be
rectified.
3. At least 60% of the target sample size can be
recruited.
4. At least 60% of participants in each treatment arm
receive a minimum adequate dose of treatment
(attend at least 50% of possible sessions).
5. Follow-up data on candidate primary outcome
measures are available for at least 60% of the target
sample size at 6, 12, and 18 months.
Method
This protocol is reported according to the SPIRIT 2013
statement (see Additional file 1: SPIRIT figure; see Add-
itional file 2 for a completed SPIRIT checklist).
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The aim of the study is to evaluate proof of concept,
feasibility, and acceptability of ADepT and to evaluate
the feasibility of a definitive randomised controlled de-
sign comparing ADepT to CBT in the treatment of
depression.
Design
This is a single-site pilot study, using a two-arm rando-
mised parallel controlled trial design. Participants will be
randomised using a 1:1 ratio to either ADepT or CBT.
Outcome and health economics measures will be taken at
baseline and at 6-, 12-, and 18-month post-randomisation
(with 6months as the primary end point). Quantitative
self-report process evaluation measures will be taken at
intake, 4 and 8 weeks into treatment, immediately
post-treatment, and at 6 months. A qualitative evaluation
will be undertaken at 6 and 18months.
Study setting
The trial will be conducted at the Accessing Evidence
Based Psychological Therapies (AccEPT) clinic, University
of Exeter, UK (a NHS commissioned out-patient service).
Participants
Eligible participants will be aged over 18 years, meet cri-
teria for a current major depressive episode based on a
Structured Clinical Interview for Diagnosis (SCID-I)
[40], and score in the clinical range of the Patient Health
Questionnaire 9 (PHQ-9) [41] with marked anhedonic
features (PHQ-9 total score of 10 or more; item one
measuring anhedonia score of two or more). Participants
will describe depression as their primary presenting
problem and have sufficient knowledge of written and
spoken English to be able to make use of the therapy
and to complete research assessments without the need
for a translator.
Exclusion criteria will include schizophrenia, bipolar
disorder, learning disability, organic brain change,
currently receiving any other psychosocial therapy, sub-
stance abuse that compromises ability to use therapy,
current marked risk to self (self-harm or suicide) that
cannot be safely managed in the clinic setting, and/or
other significant conditions that mean the participant
will not be able to participate in the trial (or will be put
at risk by doing so).
Participants will have travel costs reimbursed and be
given a £10 honorarium for each research assessment
(intake and 6, 12, and 18months) they complete (but
not for attending each treatment session).
Sample size
We aim to recruit 80 participants (40 per treatment)
arm. Assuming a retention rate of 80% during the trial,this will lead to 32 treatment completers with complete
data. This sample size will allow us to address the proof
of concept and feasibility objectives of the pilot trial with
sufficient precision and efficiency [42] (see Table 1).Randomisation, allocation concealment, and blinding
Participants will be randomly allocated to either the
CBT or ADepT arm in a 1:1 ratio, stratified by symptom
severity using published cutoffs on the PHQ-9 (< 19 ver-
sus ≥ 19) and antidepressant usage (currently taking an-
tidepressants versus not) (cf. [39]). A computer-based
system will allocate the first 24 participants on a truly
random basis, with 12 participants being allocated to
each arm using a pre-generated static list. For subse-
quent participants, the allocation will use a minimisation
method in order to maximise the likelihood of balance
in stratification variables across the two treatment arms.
Randomisation will occur after baseline assessments.
Concealment will be ensured by the use of an exter-
nally administered password-protected trial website, set
up and maintained by the UKCRC accredited Peninsula
Clinical Trials Unit, independent of the trial. The trial
manager (EW) and administrators of the AccEPT clinic
(who are independent of the trial team) will be the only
people aware of treatment allocation.
The intake assessment will be completed prior to ran-
domisation, so blinding is not required at this stage. All
researchers conducting 6-, 12-, and 18-month assess-
ments will be blind to allocation.Recruitment
The primary method of recruitment will be from
waiting lists held by high intensity Improving Access
to Psychological Therapies (IAPT) services in Devon.
If required, we may broaden our recruitment strategy
by recruiting patients from general practices on the
basis of record searches and seeking referrals from
local mental health assessment teams and other local
psychology therapy providers (including the AccEPT
clinic hosting the research). Members of staff in each
recruitment setting will identify and approach eligible
patients and invite them to return a permission to
contact form to the research team. If clients return
the permission to contact form, a member of the re-
search team will then invite them to attend an initial
assessment at the AccEPT clinic, sending a detailed
information sheet for clients to read in advance of
this appointment. This initial assessment (conducted
by EW) will describe the study in full, determine par-
ticipant eligibility, and take written, informed consent.
Ineligible participants or those who wish to not take
part will have their care handed back to the service
from which they were referred.




Recruiting 80 individuals allows an estimation of recruitment rate from our primary recruitment source of 30% with a
margin of error of ± 5.80%, of 20% with a margin of error of ± 5.07%, and of 40% with ± 6.20% (according to the 95%
confidence interval). Assuming a 30% recruitment rate, this will require contacting approximately 270 clients. Assuming a




Recruiting 80 participants will enable estimation of retention rate (as a percentage of patients randomised) of 80% with a
margin of error of ± 8.77%, of 70% with a margin of error of ± 10.04%, and of 90% with a margin of error of ± 6.57
(according to the 95% confidence interval).
Estimation of rate
outcomes
Sixty-four individuals being retained allows estimation of a sutained recovery rate of 60% with a margin of error of ±
12.00%, of 70% with a margin of error of ± 11.23%, and of 50% with a margin of error of ± 12.25% (according to
the 95% confidence interval).
Effect size estimates in
ADepT arm
According to Cohen’s rules of thumb, at 80% power in a paired sample t test, a sample size of at least 13 is required
to detect a large effect size (d ≥ .8), a sample size of at least 32 is required to detect a medium effect size (d ≥ .5),
and a sample size of at least 197 is required to detect a small effect size (d ≥ .2). Therefore, assuming expected levels
of recruitment and attrition, these analyses are powered to detect a medium or large pre- to post-treatment change in
the ADepT arm for candidate outcome and mechanism measures to inferentially test proof of concept.
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ADepT arm
We will provide a detailed description of the ADepT inter-
vention protocol to enable replication, evidence synthesis,
and wider implementation (cf. [29, 43]). ADepT is made up
of novel intervention elements translated from basic science
and also integrates intervention elements from a range of
existing treatments, including CBT [24, 44, 45], Acceptance
and Commitment Therapy [46], Positive CBT [47],
Strengths-Based CBT [48], Wellbeing Therapy [49],
Goal-Setting and Planning (GAP) approaches [50], Behav-
ioural Activation [51], Mindfulness-Based Cognitive Ther-
apy [52], Future Directed Therapy [53], the Cognitive
Behavioural Analysis System of Psychotherapy [54], and
Dialectical Behaviour Therapy (DBT) [55]. ADepT also inte-
grates ideas from the positive psychology literature [56, 57].
The acute phase of ADepT consists of up to 15 indi-
vidual therapy sessions (delivered approximately weekly
and aiming to be completed within 6 months). As de-
pression often has a chronic relapsing course, to help
sustain long-term wellbeing, an additional five optional
booster sessions (scheduled flexibly over the year follow-
ing acute treatment) are offered to clients. This means
treatment in total can be of up to 20 sessions across an
18-month period. Each session will last 60 min, with the
exception of the initial assessment which can last up to
90min. Sessions will typically be delivered face-to-face
in a therapy room, although at times may be conducted
over the telephone.
To overcome the pervasive, negatively biased information
processing that characterises depression, ADepT therapists
will be trained to adopt a positive, solution-focused style,
‘thickening the positive narrative’ wherever possible when
clients exhibit pockets of resilience and thriving. The
intention is to build an alternative positive information pro-
cessing habit [58, 59], developing, generalising, and sustain-
ing positive ways of thinking in clients [47, 48, 60]. Thefocus in ADepT is primarily on the ‘here and now’ and the
future [53, 61]. Clients are supported to develop a positive,
recovery-oriented relationship to their depression [62], see-
ing it as something that they can learn to manage well so
that it does not get in the way of living the life they wish to
lead. There is an emphasis on turning depressed clients into
their own environmental change agents, building a positive,
reinforcing communication style to enable clients to shape
their work, hobbies, and relationships and to skilfully seek
social support from others.
Given increasing evidence that therapy outcomes are
improved if treatment is memorable, therapists will use
techniques to enhance memorability of sessions (atten-
tion recruitment, categorisation, evaluation, application,
repetition, practising remembering, use of cue-based re-
minders, and praising recall) [63, 64]. Clients will also be
given handouts summarising the key learning points
covered in each session and explaining how to use the
ADepT tools. This is to help clients consolidate learning
from each session (and also to ensure they have
resources in the future if they wish to revisit what was
covered in session).
Each session will utilise the following structure: con-
ducting a mood review, setting an agenda, reviewing
homework, working through each agenda item, and then
asking the client to summarise and give feedback on the
session. Home practice and exercises will be set between
sessions. Therapists will actively seek and act on feed-
back from clients about how to make sessions most use-
ful. Table 2 provides a breakdown of the approximate
content covered in each session (although therapists will
be encouraged to tailor when and whether different ele-
ments are introduced to match client needs).
A bespoke ADepT training manual has been devel-
oped for the purposes of this trial. Therapists will attend
an initial 1-day training workshop to familiarise them-
selves with the rationale of the approach, to learn key
Table 2 Session by session content in ADepT intervention
Session Description
1 Assess the clients’ depression, review what is currently helping and not helping about how they are managing it, and introduce
the ADepT rationale and structure.
Home activities: Read treatment rationale handout, watch ‘BlackDog’ video about living with depression, and complete
mood diary
2 Review mood diary and reaction to rationale and video; identify values in vocational, relationship, self-care, and leisure domains; and
introduce to ‘dartboard’ exercise. This involves rating how close to the ‘bullseye’ behaviour is to key values in each life domain.
Home activities: Read values handout, refine values, and complete mood diary
3 Review mood diary and values homework, set values consistent goals in each life domain using extended ‘dartboard’ exercise.
Home activities: Read goals handout, refine goals, and complete mood diary
4 Review mood diary and goals handout, use a goal planning and monitoring tool to break goals down into SMART action steps, and build
the capability, opportunity and motivation to carry out each action step.
Home activities: Read goal planning and monitoring tool handout and use to address one goal, read handout about overcoming snags
that block goal pursuit
5 Review use of goal planning and monitoring tool. Introduce to mapping tool, which formulates mechanisms that help/hinder resilience/
thriving. This tool can be used to map out an ‘old me’ (depressive coping) and to develop a ‘new me’ (constructive coping) in a
given situation. The ‘new me’ formulation will be utility based, focusing on what the goal is in a given situation and then what would
be a way of thinking and behaving that would be most likely to bring this about.
Home activities: Use mapping tool to analyse one opportunity and one challenge in the next week
6 Review use of mapping tool. Introduce to positive diary keeping to capture moments of resilience and thriving. This intends to build a
positive, specific memory, and attentional style.
Home activities: Read handout on positive diary, complete positive diary for next week
7 Introduce to mindful engagement with everyday wellbeing activities that enhance pleasure, meaning, and social connection.
Home activities: Read handout on everyday wellbeing activities, practice mindful engagement with everyday activities, and continue to
complete action steps
8 to 12 Use above tools to work through action steps identified above and develop new ways of coping when engaging with opportunities and
challenges (‘acting opposite’ to depressive mechanisms). This will consist of psychoeducation around mechanisms, skills training around
alternative ways of coping, and conducting behavioural experiments to test out and refine these new ways of coping.
Home activities: Dependent on client goals and learning needs
13 to 15 Develop wellbeing plan to continue to build wellbeing in months after therapy. This can include reviewing goal progress and setting
future goals on ‘dartboard’, reviewing key mechanisms helping/hindering resilience/thriving on formulation tool, reviewing key therapy
techniques using a checklist, formulating a ‘relapse signature plan’ (early warning signs mood is dropping and steps that will be taken
to minimise this), formulating a ‘wellbeing signature plan’ (early indicator signs mood is lifting and steps they will take to maximise this),
and sustaining engagement with everyday wellbeing activities and ‘positive review’. If useful, a carer/partner can be invited into later
ADepT sessions to share learning and support the client with ongoing change after acute therapy has completed.
Home activities: Read and complete wellbeing planning tools
16 to 20 Five optional booster sessions will then be offered over the year after therapy. These will be used to review progress with goals, celebrate
success, and troubleshoot any difficulties.
Home activities: Dependent on client goals and learning needs
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style. They will then be given detailed notes describing
the aims and content of each session, with example
audio clips from sessions with previous clients to illus-
trate ways of working (a detailed paper describing the
ADepT protocol and presenting some case examples is
to follow). Therapists will also be encouraged to practice
ADepT techniques on themselves. Therapists will be re-
cruited who have background in CBT (including clinical
psychologists, nurses, and other high intensity trained
therapists from Improving Access to Psychological Ther-
apies Services). ADepT supervision will be provided in a
small group format of 90 min weekly. Supervision and
training will be provided by the project principal investi-
gator (BD: an accredited CBT therapist and developer of
the ADepT approach). Therapy competence and adher-
ence to the ADepT protocol will be assessed with a be-
spoke fidelity rating tool.CBT
CBT will consist of up to 20 (approximately weekly) indi-
vidual therapy sessions over a 6-month period, following
the CBT protocol developed in the COBRA trial [39, 65].
This protocol is predominantly based on the original
Beckian CBT [24], updated to manage treatment-resistant
depression [44] and to use a strengths-based formulation
approach [45]. CBT focuses on engaging clients with
pleasant activities and then identifying and modifying pat-
terns of negative thinking that maintain the depressed
mood. Sessions will again last up to 60min each, supple-
mented by home practice between sessions. A 1-day
top-up training will be provided to orient therapists to the
trial and to familiarise themselves with the CBT protocol.
CBT supervision (by accredited CBT therapists with ex-
perience in supervision of this protocol) will be provided
in individual or small group format (up to 90min per
week as required). As in the ADepT arm, psychological
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deliver CBT in the trial and therapist competence and ad-
herence will be measured using a fidelity rating tool.
Clinical outcome assessments
Assessments will be conducted face-to-face or over the
telephone at intake and 6, 12, and 18 months post-baseline.
All participants will be invited to complete these assess-
ments, irrespective of whether they deviate from the treat-
ment protocols. The candidate co-primary outcome
measures are the 9-item PHQ-9 [41] to measure depression
symptoms and the 14-item Warwick-Edinburgh Mental
Wellbeing Scale (WEMWBS) [66] to assess wellbeing.
Changes in anhedonia and positive affect (key features of
depression that ADepT specifically targets) will be mea-
sured using the 20-item Positive and Negative Affect
Schedule (PANAS) [67] past-week version, the 14-item
Snaith-Hamilton Pleasure Scale (SHAPS) [68], and the
10-item anhedonic depression subscale of the 30-item
Mood and Anxiety Symptoms Questionnaire (MASQ-D30)
[69]. Participants will also complete the 7-item Generalized
Anxiety Disorder Scale (GAD-7) [70] to measure anxiety
symptoms and the 10-item anxious arousal and 10-item
general distress subscales of the MASQ-D30 [69]. The re-
searcher will administer the Structured Interview Guide for
the Hamilton Depression/Anxiety Rating Scales (SIGH-D
and SIGH-A) [71, 72] to assess anxiety and depression se-
verity and the Structured Clinical Interview for Depression
(SCID) [40] to assess current depression diagnostic status.
At 12- and 18-month assessments only, the Longitudinal
Interval Follow-up Evaluation (LIFE) [73] will be used to as-
sess depression diagnostic status over the previous
6-month period.
Complying with minimum data set requirements for
Improving Access to Psychological Therapy (IAPT) ser-
vices, immediately prior to each therapy session, partici-
pants in both arms will also complete the PHQ-9 [41],
GAD-7 [70], IAPT phobia scale [74], Work and Social
Adjustment Scale [75] to measure functional impair-
ment, and IAPT employment questions to assess em-
ployment status. Given the anhedonia/wellbeing focus of
ADepT, all participants will additionally complete the
short form of the PANAS past-week version [76] as a
measure of positive and negative affect, and the short
(seven-item) version of the WEMWBS [77]. These
weekly measures will make it possible to examine the
trajectory of change on each outcome during acute
treatment, informing when process evaluation mechan-
ism of change measures should be optimally adminis-
tered in a subsequent definitive trial. Successful
acquisition of outcome data prior to every treatment ses-
sion in routine IAPT service settings in the UK National
Health Service indicates that it is feasible to collect
weekly data in this way.Health economic outcome assessment
The health economics will take a NHS and personal
social services perspective. Participants will complete
the following health economic measures at baseline
and at 6-, 12-, and 18-month follow-up: the Adult
Service Use Schedule (AD-SUS)(see [78, 79]) to cap-
ture health/social care services used, the absenteeism
and presenteeism items of the World Health Organ-
isation Health and Performance Questionnaire (HPQ)
[80] to index productivity losses, the EuroQol five di-
mensions questionnaire (EQ-5D-5L) [81] as a
health-related quality of life index, and the ICEpop
Capability measure for Adults (ICECAP-A) [82] as a
wellbeing-related quality of life index. Socio-economic
status will be measured by assigning participants an
occupation code [83] and asking them about employ-
ment status, the size of the organisation they work in
(if appropriate), and if they have supervisory experi-
ence (if appropriate). We will examine the utility of a
resource log (a diary that participants can fill in each
time they make use of services to serve as a memory
aid) [84] to help capture service use in the definitive
trial. The first 40 participants will be given a resource
log at baseline, and the second 40 participants will
not be given the resource log, allowing us to examine
whether the resource log enhances the capture of
health service utilisation data. Information on the re-
source use and costs of delivering the ADepT and
CBT treatments (including sessions attended, can-
celled, and DNAs; amount of time spent training and
in supervision) will be collected.
Treatment fidelity assessment
With participants’ consent, all sessions will be audio re-
corded. A random sample of up to 20% of all tapes,
stratified by therapist, therapy session, and intervention,
will be assessed by independent raters for competence
rating using the Cognitive Therapy Scale-Revised [85]
for the CBT arm and the bespoke ADepT supervision
rating tool for the ADepT arm.
Quantitative process evaluation
Consistent with MRC guidance about how to conduct
process evaluations of complex interventions [86], a
series of self-report questionnaire measures will be ad-
ministered at baseline, after session 4, after session 8,
after the final acute treatment session, and at 6-month
follow-up to test the a priori specified ADepT logic
model of change. To assess if clients have identified and
are working towards value consistent goals, participants
will complete a bespoke 20-item values rating scale de-
veloped for the purposes of this study (ADepT values
rating scale; AVRS). The 12-item Savouring Beliefs In-
ventory (SBI) [87] will assess the capacity to thrive. The
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10) [88] will assess resilience. The 10-item General Effi-
cacy Scale (GSE) [89] will assess self-efficacy. The
10-item Internalised Stigma of Mental Illness Scale
(ISMI-brief ) [90] will assess clients’ relationship to their
depression. To assess the quality of the therapeutic alli-
ance, participants and therapists will complete the
10-item Working Alliance Inventory-Short Revised Form
(WAI-SR and WAI-SRT) [91] after session 4, session 8,
and final acute treatment session.
Change in key mechanisms impacting on resilience
and thriving will be assessed using the following scales:
avoidance via the 9-item Behavioural Avoidance in De-
pression Scale (BADS-SF) [92], rumination via the
10-item Ruminative Response Scale of the Ruminative
Responses Questionnaire (RSQ) [93], self-criticism via
the 12-item Self-Compassion Scale Short Form (SCS-SF)
[94], mind wandering via the 15-item Five Facet Mind-
fulness Questionnaire Short Form items on acting with
awareness (FFMQ-SF) [95], dampening appraisals via the
dampening scale of the Response to Positive Affect Scale
(RPA) [96], and disconnection from sensory and bodily
awareness via a bespoke 6-item Brief Awareness of
Everyday Sensory Experiences (BASE) scale developed
for the purposes of this trial.
To assess momentary affective experience in day-to-day
life, participants will undergo the experience sampling
method (ESM) at intake and 6months only (not at 12- or
18-month follow up to minimise participant burden).
ESM is a momentary assessment technique in which par-
ticipants are prompted to report on their current experi-
ences at multiple moments during the day. ESM is
therefore ideally suited to investigate changes in people’s
emotional reactions to their daily environment in a reli-
able, ecologically valid fashion that minimises retrospect-
ive memory bias [97]. Participants will be lent a phone
and then asked to use a bespoke application to answer a
series of questions at eight daily intervals (one prompt de-
livered at a quasi-random time within each 2-hour period
of the waking day) in the week before treatment starts and
for a week following the 6-month outcome assessment
(adapting methodology used by [98]). At each time point,
positive and negative mood will be assessed by average
rating of experience of a series of positive and negative
emotion states in the present moment, on a sliding visual
analogue scale ranging from 1(not at all) to 100 (ex-
tremely). Participants will also answer a series of questions
that assess their levels of wellbeing, resilience, and thriving
and use of psychological mechanisms targeted by ADepT
treatment, using the same visual analogue scale. A series
of multiple response items will classify the nature of the
activity the participant is completing at that time. ESM
data have a hierarchical structure. Multiple observations
(level 1) are clustered within participants (level 2).Multilevel linear regression analyses take the variability as-
sociated with each level of nesting into account [99] and
will be used to analyse the ESM data.
The following laboratory experimental measures of
mechanism of change will also be administered at base-
line and 6months only to assess positive versus negative
information processing biases. A valenced dot probe task
will be used to measure attentional bias to positive ver-
sus negative material (VDP) [100]. The Psychological
Distance Scaling Task (PDST) [101, 102] will be used to
measure positive versus negative schema organisation.
The Probabilistic Selection Task (PST) [103] will be used
to measure how quickly participants learn from positive
versus negative reinforcement contingencies. Fig. 2 sum-
marises how the various mechanism measures test the
logic model of change.
To assess acceptability of the interventions, the follow-
ing ratings will be taken. Following their first treatment
session, participants in both arms will complete the
six-item credibility/expectancy questionnaire (CEQ)
[104] to gain their initial views on treatment. At 6
months, participants in both arms will be asked to rate
the acceptability of the treatment they received (from 1
= not at all acceptable to 5 = very acceptable), how satis-
fied they were with the treatment they received (from 1
= not at all satisfied to 5 = very satisfied), and how likely
they would be to recommend that treatment to friends
or family if they needed similar care or treatment (from
1 = extremely likely to 5 = extremely unlikely). These
questions will be repeated at 12 months, and participants
in the ADepT arm will additionally be asked how useful
they found the booster sessions on a scale (from 1 = not
at all useful to 5 = very useful).
Qualitative process evaluation
Patient and clinician experience and views on ADepT
treatment and trial processes will be canvassed in a var-
iety of ways, allowing us to further evaluate mechanisms
of impact and also to explore implementation issues and
any modifying influence of contextual factors (consistent
with MRC guidance on process evaluation) [86]. This
will help us understand the acceptability of the interven-
tion and optimise its subsequent refinement, both in
terms of running a future definitive trial but also in
terms of whether ADepT could be implemented and sus-
tained in routine NHS services in the future if it is
shown to be clinically effective and cost effective.
A feedback booklet will be given to all participants at
6 months to allow them to provide brief written
accounts of their experience of treatment and taking
part in the research study. A subsample of participants
will then be invited to a face-to-face qualitative inter-
view, estimated to be 30 participants, or until data satur-
ation has been reached. Recruitment will be purposive,
Fig. 2 How process evaluation measures assess logic model of ADepT
Dunn et al. Pilot and Feasibility Studies            (2019) 5:63 Page 9 of 16seeking to achieve maximum variation in relation to
(i) treatment arm (mixture of ADepT and CBT), (ii)
completion/non-completion of treatment (based on
minimum adequate dose of eight or more sessions),
and (iii) response/non-response to treatment (based
on a drop of PHQ-9 of 6 points or more during
acute treatment). Subsampling will also be informed
by participants’ written responses in the feedback
booklet and will give us the opportunity to explore
any unanticipated experiences and effects in more
depth. Interviews will be conducted within 6 months
of completing the feedback booklet (i.e. before the
12-month follow-up), will last approximately 45 min,
and will explore participants’ experiences of the ther-
apy and trial procedures at the end of acute treat-
ment. The interviews will follow a topic guide to
ensure that all areas are covered, but this will be used
flexibly so as to allow other issues of importance to
participants to be fully examined.
At 18-month follow-up, all participants in the ADepT
arm will complete a further written feedback booklet,
asking about their views on and experience of the
booster sessions in ADepT.
All therapists and supervisors will also be invited to
take part in a 45-min qualitative interview at the end of
the trial to explore their views on treatments (including
their views on feasibility, acceptability, efficacy, mechan-
ism of change, and implementation) and on trial design.
Due to resourcing constraints, both the quantitative andqualitative process evaluation will be conducted by the
trial team rather than by independent researchers.
Establishing minimum clinically important difference for
outcome measures
To calculate anchor-based estimates of minimum clinic-
ally important difference (MCID) on the candidate out-
come measures, at 6 and 18 months, participants will be
asked to rate whether they feel that treatment led them
to feeling very much better, much better, a little better,
no change, a little worse, much worse, or very much
worse in terms of their levels of depression symptoms,
anxiety symptoms, wellbeing, anhedonia symptoms, and
positive and negative mood (using a modified version of
the Clinical Global Impressions Scale for each symptom
class) [105]. These answers will be cross-matched to the
degree of change that participant showed on each candi-
date measure to help establish mean and median
amount of change that corresponds to each category. To
calculate distribution-based estimates of MCID, we will
calculate the standard deviation on each measure at in-
take (collapsing across treatment arms). Consistent with
previous studies [106], we will use improvements of at
least half a standard deviation to indicate clinically im-
portant change.
To capture participants’ views on outcome measures,
at 18 months, participants will be given a copy of the
measures to review and will then be asked to answer a
series of questions about each of them in turn. First,
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statement that the measure captures what it is important
to improve on during treatment for depression, on a
scale from 1 (strongly agree) to 5 (strongly disagree).
Second, participants will estimate clinically important
change on that measure (defined as the smallest amount
of change for them to feel the treatment had made a dif-
ference which was worth having treatment for). Third,
participants will be given the opportunity to give narra-
tive comments about what they think of that measure.
Finally, participants will rank the measures from 1 (best)
to 5 (worst) in terms of which is the best measure to use
in the definitive trial to indicate whether treatment has




Prior to quantitative analysis, data anonymization,
checking and cleaning will be conducted and the
database finalised by the trial manager (EW). The pri-
mary analyses will be conducted when the 6-month
follow-up is complete (with further analyses at 12
months and 18months). Feasibility analyses will use
complete case data only. Inferential proof of concept
analyses will be conducted on an intention to treat basis
and will utilise multiple imputation to model missing
data (only if assumptions regarding random missingness
of data are met). Analyses will be conducted by the prin-
cipal investigator (BD), who will remain blind to treat-
ment condition until after the 6-month follow-up
analyses have been completed.
Proof of concept analyses
All continuous (mean and SDs) and categorical (percent-
ages) clinical outcomes and mechanism measures will be
reported descriptively for each arm at each assessment
point. We will report the proportion of participants in
each arm showing reliable change and reliable and clin-
ically significant change (cf. [38] at 6 months, 12 months,
and 18months, relative to baseline data, on each clinical
outcome measure. We will use estimates of minimum
clinically important difference derived from the trial to
determine the cutoff for clinically significant change.
Paired sample t tests will assess whether there is a sig-
nificant improvement, relative to baseline, at each as-
sessment point on each outcome measure and
mechanism measure for participants in each arm. We
will report the effect size for each of these analyses
(Cohen’s d; Cohen, 1988; with 95% confidence intervals)
and interpret them according to existing rules of thumb
(< .2 = negligible, .2 to .5 = small, .5 to .8 =medium, and
> .8 = large). To allow benchmarking against outcomes
in routine NHS IAPT care, we will report the proportionof clients in each arm at 6-month assessment meeting
IAPT criteria for reliable improvement (> 6 point reduc-
tion on the PHQ-9), recovery (PHQ-9 < 10 and GAD-7
< 8), and reliable recovery (meeting both reliable im-
provement and recovery criteria). To allow benchmark-
ing with previous depression trials, we will also report
the proportion of clients in each arm at 6-month
assessment meeting criteria for response (> 50% drop
in symptoms from intake) and remission (scoring
beneath clinical cutoffs) on the PHQ-9 and HDRS. For
the PHQ-9, the remission cutoff is scoring < 10, and for
the HDRS, the remission cutoff is scoring < 8. For the
subset of participants who no longer meet diagnostic
criteria for a major depressive episode at 6 months, we
will also report the proportion of individuals in each
arm who show sustained recovery (i.e. do not meet diag-
nostic criteria at any time during the follow-up phase) at
12months and 18months. For those who relapse, we will
report the mean time to relapse in each arm. We will
also report the number of people showing a
treatment-related serious adverse reaction in each arm.
Feasibility and acceptability of ADepT intervention
For each arm, we will report the number of participants
who (i) withdrew from the trial prior to randomisation
and indicated that this was because they could not re-
ceive their preferred treatment and (ii) who withdrew
from the trial during active treatment and stated this
was due to dissatisfaction with the treatment. Patient ad-
herence to treatment will be indexed by the mean (SD)
number of therapy sessions offered and attended and by
calculating the proportion of participants who receive a
minimum adequate dose (eight or more sessions) in
each arm. To determine initial views on acceptability of
each treatment, mean (SD) of session one CEQ [104] rat-
ings will be reported. To determine post-treatment views
on acceptability, participants mean (SD) ratings of treat-
ment acceptability and satisfaction and whether they
would recommend treatment to friends and family at 6
months and 18months will be reported.
Refinement of fidelity ratings
To evaluate and refine how well procedures and tools
rating therapy quality and adherence to protocol are
functioning, we will assess the proportion of clients who
give consent for sessions to be recorded and the propor-
tion of sessions where the recording is captured in a way
that can then be coded. We will assess the inter-rater re-
liability of this ADepT fidelity tool, selecting a random
subset of session tapes in the ADepT arm to be rated by
two experienced clinician raters. We will also ask experi-
enced clinicians and supervisors to review the fidelity
tool and listen to example tapes to set a cutoff for adher-
ence i.e. the therapy is competently delivered, in a way
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ates it from CBT. We will revise the tool as appropriate.
Selecting outcome measures and informing sample size
calculations
Mean (SD) patient rankings of each candidate outcome
measure will be reported. Patient, clinician, and super-
visor narrative views on each outcome measure will be
thematically summarised. Minimum clinically important
difference will be estimated for each candidate outcome
by averaging findings from distribution, anchor, and
patient report methods. The estimate of MCID and
standard deviation at baseline of each measure will be
combined to inform sample size calculations for a subse-
quent definitive trial (i.e. to calculate how many partici-
pants would be required to test MCID superiority of
ADepT over CBT).
Informing recruitment for definitive trial
For each recruitment source, we will report the number of
individuals identified, approached, consented, and rando-
mised into treatment. We will also report the total number
of participants randomised to treatment each month. For
each arm, we will report the number of individuals complet-
ing acute treatment. For the ADepTarm only, we will report
the number of individuals completing booster sessions.
Refining trial procedures for definitive trial
We will report the percentage of time researchers accur-
ately guessed the blind (examining if this is significantly
greater than chance) in each arm. Further, for each arm,
we will report the number of times the blind was clearly
broken, where the online randomisation system failed,
where there were problems in subsequent allocation to
treatment after randomisation, and where capture of
outcome data failed (e.g. computer failure during experi-
mental tasks), and the proportion of participants with
complete data at each assessment point.
Health economic data
To estimate the costs of the two interventions for health
economic purposes, resources involved in delivering
CBT and ADepT will be collated directly from therapists
(including training, supervision, and travel time).
Intervention costs will be calculated via standard
micro-costing (bottom-up) approaches, incorporating
therapist salaries plus on-costs (pension/national insur-
ance contributions) and appropriate capital, administra-
tive, and managerial overheads. Descriptive data for each
arm will be reported with 95% confidence intervals. To
resolve uncertainties about health economic data com-
pleteness, we will test data collection procedures and
record resource use categories prone to missing data/be-
ing misunderstood in self-report measures. To evaluateresource log utility, we will randomly sample a subset of
individuals either given or not given the log and examine
the degree to which resource use reported in the patient
questionnaires matches medical records (via SUS or
CRIS record search if available). These analyses will in-
form whether there is a need to develop strategies to
collect missing data and/or to include proxy assessments
in the main trial. We will use this health economic data,
along with acute depression symptom and wellbeing im-
provements and 18m relapse rates observed in this trial
and other datasets, to develop the framework to model
the likely cost-effectiveness of ADepT compared to CBT
using decision tree modelling techniques [107].
Qualitative analysis
Feedback booklets will be anonymised and interviews
audio recorded, transcribed verbatim, and anonymised
prior to analysis. Thematic analysis of both qualitative
data sets will be conducted using a Framework
approach, involving the coding and sorting of textual
units according to both deductive and inductively de-
rived categories, and the use of matrices to review the
coded data, investigate commonalities and differences,
and search for patterns [108, 109]. Initial coding and
data management will be facilitated by NVivo software.
Qualitative analysis has the potential to clarify therap-
ist and clients views about whether ADepT is an effect-
ive treatment and how it may work, to gain therapist
and client views about the acceptability and feasibility of
ADepT, to gain therapist views about the training path-
way for ADepT and how this could be enhanced, to ex-
plore client views about which outcome measures best
capture what is important to them for recovery, to ex-
plore therapist and client views about barriers and facili-
tators to recruitment into the trial, to explore client
views about how taking part in the trial was experienced
and whether the measurement burden was acceptable,
and to explore client views about the utility of the re-
source log and any barriers or facilitators to accurate
reporting of resource use.
Exploratory condition analyses
While the study is not formally powered to detect condi-
tion differences, additional exploratory analyses will
examine if there are any differences between the two
treatment arms (all with condition as the independent
variable, adjusting for stratification variables of depres-
sion severity and antidepressant medication status).
Continuous outcome and process evaluation measures
across treatment arms will be compared at 6-month,
12-month and 18-month assessments using ANCOVA
analyses, adjusting for baseline outcome levels. We will
report partial eta-squared as a measure of effect size
(with 90% confidence intervals) for these ANCOVA
Dunn et al. Pilot and Feasibility Studies            (2019) 5:63 Page 12 of 16analyses (see Steiger [110]). Time to relapse/recurrence be-
tween arms at 12-month and 18-month follow-up (in the
subset of clients who recovered at six-months) will be com-
pared using Cox regression proportional hazard survival
analysis. Hierarchical linear modelling (growth curve ana-
lysis) on weekly outcomes during acute treatment will
examine if the trajectory of change differs between arms.
We will additionally explore whether the stratification vari-
ables (severity and medication status) are associated with
condition effects, by entering interaction terms between
condition and the stratification variables into analyses. Ex-
ploratory analyses will also be conducted on the laboratory
mechanism measures (following analytic methods in exist-
ing studies using these tasks) and experience sampling
measures (using as appropriate a hierarchical linear model-
ling approach to take into account the nested structure of
the data). Finally, we will conduct exploratory Bayesian ana-
lyses to examine the expected additional benefit to new pa-
tients of being treated with ADepT rather than CBT on the
two primary outcomes of PHQ-9 depression and
WEMWBS wellbeing. We will report the 95% credibility
interval of the difference between outcomes if new patients
had been treated with ADepT rather than CBT at 6-month,
12-month, and 18-month assessment, based on a simulation
from the primary outcome model (see Lynch et al. [111]).
Trial management and governance
Data management and storage
Clinical notes, measures, and therapy recordings will be
stored according to the standard practice of the host
AccEPT clinic. Hard copies of information/measures gath-
ered as part of the research study will be anonymised and
then stored in a locked filing cabinet in a locked office in
the Mood Disorders Centre, University of Exeter. Consent
forms will be stored separately from data. Data will be en-
tered into an SPSS spreadsheet maintained by the trial
manager (EW), stored securely on the University of Exeter
server. The candidate primary outcome data [PHQ-9 and
WEMWBS] will be double entered. Published material
will not contain patient identifiable information. The
datasets generated and/or analysed will be stored in a
repository within the University of Exeter (and will not
be made publicly available). Anonymised data may be
accessed and analysed by members of the project team
and with researchers collaborating with team members
on the analysis of these data. With the exception of
anonymised quotes from research interviews, consent
from participants was not sought for sharing raw data
publically. Therefore, external researchers who wish to
access the data for future projects or analyses must do
so via request to the principal investigator (or his dele-
gate) and ensure necessary ethical and regulatory pro-
cesses in the UK relating to the release of anonymised
data have been followed.Original research records will be retained for 7 years after
the study end, after which time they will be kept in elec-
tronic form and the original records destroyed (including
records of participants’ names and contact details). Audio
files of participant interviews will be destroyed at this time
(although transcriptions of the interviews will be kept in
electronic form). The electronic records will be kept for at
least 20 years after the study end.Study approvals
The study has received approval from the UK National
Research Ethics Service (REC reference: 17/SW/0009)
and the Health Research Authority (IRAS ID: 216871),
and from all relevant local approval bodies.Anticipated risks and benefits
All participants recruited into the trial will receive up to
20 sessions of psychological therapy that is likely to be
beneficial to their mood. During the active treatment
phase of the trial, participants will be asked not to engage
with any other psychological therapy (reflecting standard
practice that only one therapy should be completed at a
time), but no other aspects of standard care will be with-
held as a result of trial participation. All participants in
the trial will receive an enhanced level of monitoring by
the research team. Individuals with depression are at in-
creased risk of self-harm and suicide compared to the gen-
eral population. The trial will follow established clinical
and research protocols for monitoring and responding to
self-harm, suicide risk, or other adverse events during
therapy and research contacts. This may involve unblind-
ing if required to ensure patient safety (asking the trial
manager for treatment allocation).Trial governance
The University of Exeter will act as sponsor for this
study. While not an essential requirement for a feasibil-
ity trial, we have convened a combined Trial Steering
Committee and Data Monitoring and Ethics Committee
(TSC/DMEC). This is independent from the sponsor; is
made up of the principal investigator (BD) and trial
manager (EW) and independent (academic, clinical,
and lived experience) members; and will meet ap-
proximately four times over the life of the project.
The terms of reference for the TSC/DMEC include
monitoring trial progress, providing advice on scien-
tific issues, and evaluating if there are any patient
safety concerns that require the trial to be modified,
paused, or discontinued. For all substantive changes
to the protocol, approval will be sought from the
sponsor and the relevant national regulatory bodies.
As appropriate, trial registration will be updated.
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The form and content of the ADepT intervention and the
trial protocol was co-designed using input from the public
and patient involvement lead on the project team (NR),
other members of the Lived Experience Group (LEG) at
the Mood Disorders Centre, University of Exeter (see
http://www.exeter.ac.uk/mooddisorders/groups/leg//), and
qualitative interviews with other service users. PPI mem-
bers will also be involved in ongoing governance of the
project, including NR meeting regularly with the PI and
attending ADepT project meetings and another LEG
member sitting on TSC/DMEC. We will follow national
good practice guidelines for involving members of the
public in research (see www.invo.org.uk.).
Adverse events
In line with other complex intervention studies, we will
monitor the occurrence of adverse events (any untoward
or unintended medical occurrence or response whether
it is causally related to the trial treatments or not). Ad-
verse events will be classed as serious if they are fatal
and life-threatening, require unplanned hospitalisation
or prolong existing hospitalisation, result in significant
disability or incapacity, or lead to any other condition
judged significant by a clinician. Any serious adverse
events that may be treatment-related will be reported to
the TSC/DMEC. If the TSC/DMEC judge the event to
be serious and treatment-related, the sponsor and NHS
ethics committee will be informed immediately and a re-
port sent to them within 14 days. If appropriate, the trial
will be temporarily halted pending investigation and ana-
lysis of the extent to which future risk can be mitigated.
If it is judged that this is not possible, the trial will be
discontinued. The same process will be followed should
information come to light that indicates that the therapy
intervention or trial procedures are unsafe.
Role of the funder and sponsor
The University of Exeter as a trial sponsor has ultim-
ate responsibility over the study (contact: Gail
Seymour; G.M.Seymour@exeter.ac.uk). The sponsor
and the funder (the NIHR) have not been involved in
the design of the study and will not have any signifi-
cant role during the execution, analysis, interpret-
ation, or publication of the study. The funder will be
required to approve the final report prior to
publication.
Dissemination
Findings will be disseminated to participants, services,
and other stakeholders at the local level through a writ-
ten summary of results and public engagement events.
Findings will be disseminated at a national and inter-
national level via conference presentations and wherepossible via media and social media. The dissemination
strategy will be co-developed with public and patient in-
volvement (PPI) input, including study co-applicant NR
and LEG.
Trial status
The trial was prospectively registered on ISTRCN on 27
March 2017 (https://doi.org/10.1186/ISRCTN85278228).
The trial opened to recruitment on 29 March 2017, and
the first patient was randomised on 19 April 2017. Re-
cruitment was completed by the end of July 2018. The
final follow-up aims to be completed by the end of De-
cember 2019. Data analysis and reporting are expected
to take a further 12 months.
Discussion
This pilot trial is designed to assess the proof of concept,
feasibility, and acceptability of Augmented Depression
Therapy (ADepT) for individuals with depression.
The findings will inform future investigation of this
approach, potentially via a definitive randomised con-
trolled trial testing its clinical effectiveness and
cost-effectiveness compared to CBT.
Additional files
Additional file 1: ADepT SPIRIT figure (DOCX 25 kb)
Additional file 2: SPIRIT checklist (DOC 121 kb)
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